Akebia Therapeutics, Inc. AKBA
We take great care to ensure that the data presented and summarized in this overview for Akebia Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKBA
View all-
Black Rock Inc. New York, NY11.6MShares$24 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$22.4 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$13 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$11.8 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$9.88 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.82MShares$7.88 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.79MShares$3.69 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.69MShares$3.47 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.38MShares$2.85 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ1.23MShares$2.53 Million0.01% of portfolio
Latest Institutional Activity in AKBA
Top Purchases
Top Sells
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AKBA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 03
2025
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
46,409
-1.78%
|
$46,409
$1.83 P/Share
|
|
Mar 03
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,144
-0.88%
|
$7,144
$1.83 P/Share
|
|
Feb 03
2025
|
Nicholas Grund Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
55,621
-11.16%
|
$111,242
$2.1 P/Share
|
|
Feb 03
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
30,202
-9.73%
|
$60,404
$2.1 P/Share
|
|
Feb 03
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,506
-2.96%
|
$101,012
$2.1 P/Share
|
|
Feb 03
2025
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
144,250
-2.65%
|
$288,500
$2.1 P/Share
|
|
Jan 31
2025
|
Nicholas Grund Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+28.12%
|
-
|
|
Jan 31
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+21.49%
|
-
|
|
Jan 31
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+18.36%
|
-
|
|
Jan 31
2025
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
701,000
+20.32%
|
-
|
|
Jan 31
2025
|
Erik Ostrowski SVP, CFO, CBO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+26.35%
|
-
|
|
Jan 17
2025
|
Ron Frieson |
BUY
Exercise of conversion of derivative security
|
Direct |
20,100
+17.65%
|
$0
$0.45 P/Share
|
|
Jun 28
2024
|
Erik Ostrowski SVP, CFO, CBO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+50.0%
|
-
|
|
Jun 06
2024
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.33%
|
-
|
|
Jun 06
2024
|
Myles Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+23.5%
|
-
|
|
Jun 06
2024
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+15.4%
|
-
|
|
Jun 06
2024
|
Leanne M Zumwalt |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+28.93%
|
-
|
|
Jun 06
2024
|
Ron Frieson |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+28.93%
|
-
|
|
Jun 06
2024
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.39%
|
-
|
|
Jun 06
2024
|
Michael W Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.23%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.93M shares |
|---|---|
| Exercise of conversion of derivative security | 20.1K shares |
| Open market or private sale | 381K shares |
|---|